TABLE 1

Patient Characteristics

No.	Age (y)	Weight (kg)	KPS	Initial GS	iPSA (ng/mL)	Initial tumor classification	Primary treatment before PRRT	PSA-T (ng/mL)	Metastases	SUV_max on ⁶⁸Ga-PSMA PET/CT
1	59	85	100	8 (4 + 4)	179.0	pT3acN1cM1b	ADT, chemotherapy	3.2	Bone, LNs	14.8
2	68	104	90	7 (4 + 3)	13.2	pT3apNxcM0	RP, EBRT, ADT	2.2	Bone, LNs	12.4
3	53	76	70	9 (4 + 5)	838.0	cT3N2cM1	ADT, chemotherapy	2,518.0	Bone, BM, LNs	35.2
4	78	88	90	7 (4 + 3)	5.2	pT2cN0cM0R0	RP, EBRT, ADT, chemotherapy	43.63	Bone, LNs	84.9
5	62	84	60	9 (4 + 5)	10.4		RP, ADT, chemotherapy	1,242.0	Bone, LNs	54.7
6	66	65	80	8 (4 + 4)	48.0		ADT, chemotherapy, EBRT	314.6	Bone, LNs	15.0
7	67	111	80	10 (5 + 5)	22.0	pT3bpN1pL1pV1	RP, ADT, denosumab	107.0	Bone, LNs, lung	78.2
8	53	88	100	9 (4 + 5)	202.7	pTxN1M1c	ADT, EBRT	15.4	Bone, LNs	18.8
9	63	107	80	10 (5 + 5)	88.0	pT3bpN1M0L1V0	RP, EBRT, ADT, chemotherapy	162.2	Bone, LNs	114.5
10	73	73	80	7 (4 + 3)	15.0		RP, chemotherapy, ADT	3.4	LNs, liver	21.9
11	68	92	80		12.0	pT3cPn0M0	RP, ADT, chemotherapy	203.4	Bone, LNs	42.3
12	62	68	70	8 (4 + 4)	140.0		ADT, chemotherapy	166.3	Bone, BM, LNs, adrenal, renal, muscle	87.5
13	68	74	80		163.0		ADT, chemotherapy, EBRT	84.4	LNs	46.2
14	62	67	90	8 (4 + 4)	198.0	cT4cN1cM1	ADT	1,209.0	Bone, BM, LNs	104.5
15	68	86	100	7 (4 + 3)		pT3bpN0pM0L1R1	RP, EBRT, ADT, denosumab, chemotherapy	176.9	Bone, LNs, liver	32.5
16	65	85	70	9 (4 + 5)	4.9	pT3N0	RP, ADT, chemotherapy, PI3K inhibitor, mTOR inhibitor	207.0	Bone, BM, LNs, lung, left renal	52.6

KPS = Karnofsky performance status; GS = Gleason Score; iPSA = initial prostate-specific antigen; PSA-T = PSA before first cycle of PRLT; ADT = androgen deprivation therapy; LNs = lymph nodes; RP = radical prostatectomy; EBRT = external-beam radiotherapy; BM = bone marrow; PI3K = phosphoinositide 3-kinase; mTOR = mechanistic target of rapamycin.